

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Versant Venture Capital VI, L.P.</u> <hr/> (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 <hr/> (Street) SAN FRANCISCO CA 94104 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Century Therapeutics, Inc. [ IPSC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/09/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/09/2022		s <sup>(1)</sup>		550,000	D	\$13.0302 <sup>(2)</sup>	11,816,814	D <sup>(3)</sup>	
Common Stock	08/09/2022		j <sup>(4)</sup>		364,800	D	\$0.00	11,452,014	D <sup>(3)</sup>	
Common Stock								714,095	I	See Footnote <sup>(5)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Versant Venture Capital VI, L.P.  


---

 (Last) (First) (Middle)  
 ONE SANSOME STREET  
 SUITE 3630  


---

 (Street)  
 SAN FRANCISCO CA 94104  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Versant Ventures VI GP, L.P.  


---

 (Last) (First) (Middle)  
 ONE SANSOME STREET  
 SUITE 3630  


---

 (Street)  
 SAN FRANCISCO CA 94104  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person*		
<a href="#">Versant Ventures VI GP-GP, LLC</a>		
(Last)	(First)	(Middle)
ONE SANSOME STREET SUITE 3630		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Versant Vantage II, L.P.</a>		
(Last)	(First)	(Middle)
ONE SANSOME STREET SUITE 3630		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Versant Vantage II GP, L.P.</a>		
(Last)	(First)	(Middle)
ONE SANSOME STREET SUITE 3630		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Versant Vantage II GP-GP, LLC</a>		
(Last)	(First)	(Middle)
ONE SANSOME STREET SUITE 3630		
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)

**Explanation of Responses:**

1. The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital VI, L.P. ("Versant VI").
2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$13.03 to \$13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
4. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant VI to its limited partners pursuant to a Rule 10b5-1 trading plan.
5. The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II"). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

**Remarks:**

[By: /s/ Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: Max Eisenberg Its: Chief Operating Officer](#)  
[By: /s/ Versant Ventures VI GP, L.P. By: Versant Ventures](#) 08/11/2022  
[By: /s/ Versant Ventures VI GP, L.P. By: Versant Ventures](#) 08/11/2022

VI GP-GP, LLC Its: General  
Partner By: Max Eisenberg  
Its: Chief Operating Officer  
By: /s/ Versant Ventures VI  
GP-GP, LLC By: Max  
Eisenberg Its: Chief Operating  
Officer 08/11/2022

By: /s/ Versant Vantage II, L.P.  
By: Versant Vantage II GP,  
L.P. Its: General Partner By:  
Versant Vantage II GP-GP, 08/11/2022

LLC Its: General Partner By:  
Max Eisenberg Its: Chief  
Operating Officer

By: /s/ Versant Vantage II GP,  
L.P. By: Versant Vantage II  
GP-GP, LLC Its: General  
Partner By: Max Eisenberg  
Its: Chief Operating Officer 08/11/2022

By: /s/ Versant Vantage II GP-  
GP, LLC By: Max Eisenberg  
Its: Chief Operating Officer 08/11/2022

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**